Preemptive use of recombinant activated factor VII: many questions but few answers

Current and Future Alternatives for Allogeneic Blood Product Transfusions

“…[16][17][18][19] The use of factor VIIa in these situations is a hotly debated matter, as many clinical trials show a significant reduction in allogeneic transfusions but statistically little significant improvement in patient mortality. 20,21 A greater number of randomised trials, rather than anecdotal case reports, are necessary to better determine the appropriate doses and therapeutic efficacy of recombinant factor VIIa for the prevention and treatment of haemorrhage in patients without haemophilia.…”